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Activation of the coagulation system is a fundamental host defense mechanism. Microorganisms that have invaded
the body are trapped and disposed of in clots. Monocytes/macrophages are widely accepted as the main players in
the procoagulant process; however, recent evidence suggests that neutrophils also play important roles. Tissue
factor, which initiates the extrinsic coagulation cascade, is reportedly expressed on the surface of neutrophils, as
well as on microparticles derived from neutrophils. Neutrophil extracellular traps (NETs) are another source of tissue
factor. The components of NETs, such as DNA, histones, and granule proteins, also provide procoagulant activities.
For instance, DNA initiates the intrinsic pathway, histones are a strong generator of thrombin, and granule proteins
such as neutrophil elastase, cathepsin G and myeloperoxidase contribute to the suppression of the anticoagulation
systems. Although understanding of the mechanisms that are involved in coagulation/fibrinolysis in sepsis has
gradually progressed, the impact of neutrophils on thrombogenicity during sepsis remains to be addressed. Since
the importance of the connection between coagulation and inflammation is advocated nowadays, further research
on neutrophils is required.Introduction
Activation of the coagulation system is a critical step in
the prevention of bacterial dissemination as the coagula-
tion system participates in host defense via fibrin depos-
ition and thrombus formation [1]. Recently, Engelmann
and Massberg [2] introduced the term ‘immunothrom-
bosis’, which designates an innate immune response in-
duced by the formation of thrombi in microvessels and
is supported by immune cells and specific thrombosis-
related molecules to generate an intravascular scaffold
(Figure 1). Immunothrombosis facilitates the recogni-
tion, containment, and destruction of pathogens at the
infectious site, thereby protecting host integrity without
inducing major collateral damage. Once these reactions
occur systemically, however, they lead to disseminated
intravascular coagulation, and subsequently multiple
organ failure and death [3].
Monocytes and macrophages, together with platelets,
have long been regarded as the leading actors in activa-
tion of the coagulation system; however, recent evidence
has suggested that neutrophils also play important roles.* Correspondence: toshiiba@cf6.so-net.ne.jp
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2014For instance, the attenuation of thrombotic manifesta-
tions after neutrophil depletion demonstrates the signifi-
cant contribution of these cells [4]. In the early 1970s
Lerner and colleagues [5] suggested a critical role for
neutrophils in the thrombotic process, but their theory
has only recently been accepted. The cornerstone in this
field was a report on neutrophil extracellular traps
(NETs), which comprise the extracellular components of
neutrophils, including DNA, histones, and neutrophil
granule constituents [6]. The observation that NETs ex-
press pro-thrombotic and pro-coagulant functions has
attracted much attention. In addition to causing micro-
circulatory disturbances, thrombin generation by neutro-
phils has been implicated in the induction of further
inflammation through the activation of protease activated
receptors (PARs) [7,8]. PARs are G-protein-coupled mem-
brane receptors expressed by a variety of cells, including
vascular cells. Thrombin and other coagulation factors
such as factor VIIa and factor Xa activate platelets and
regulate the behavior of other cells through the activation
of these receptors. For example, PAR1 is activated when
thrombin binds to and cleaves its amino-terminal exodo-
main to unmask a new receptor amino terminus. This
new amino terminus then serves as a tethered peptide lig-
and, binding intramolecularly to the body of the receptor. The licensee has exclusive rights to distribute this article, in any medium, for 12
, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
cited. The Creative Commons Public Domain Dedication waiver (http://
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Figure 1 Neutrophils induce blood coagulation during sepsis. Neutrophils accumulate and adhere to the vascular endothelium in
collaboration with platelets during sepsis. There, they express tissue factor (TF), release TF-bearing neutrophil microparticles (NMPs), and expel
neutrophil extracellular traps (NETs) that initiate the coagulation cascade. In addition, neutrophil-derived granule proteins, especially neutrophil
elastase (NE), participate in thrombus formation by inhibiting tissue factor pathway inhibitor (TFPI) and anticoagulants such as antithrombin (AT)
and activated protein C (APC). Both thrombi formation and endothelial damage lead to substantial microcirculatory damage and organ dysfunc-
tion if they occur systemically. RBC, red blood cell.
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vated by a variety of proteases other than the coagulation
factors, such as trypsin and cathepsin G, leading to induc-
tion of proinflammatory responses in a variety of cells. Ac-
tivation of PARs upregulates endothelial expression of
tissue factor (TF), mobilization of Weibel Palade bodies
and release of von Willebrand factor [10,11]. In this re-
gard, coagulation and inflammation are the two wheels of
the host response to infection.
Consequently, knowledge of neutrophil functions is
quite important, not only for understanding how the co-
agulation system is activated but also for elucidating the
mechanisms involved in inflammation and host defense.
Although anticoagulant therapy could be the treatment
of choice for patients with sepsis [12], concurrent effects
on neutrophils should be considered. We expect that
such approaches may lead to the development of new
strategies for controlling severe sepsis.
Tissue factor expression
TF is a trans-membrane protein that initiates the coagu-
lation cascade and results in thrombin generation [13]. It
binds to the coagulation factor VIIa to activate factor X,
forming a transient ternary complex. During sepsis, TF is
generally accepted to be the main initiator of coagulation.
Physiologically, circulating blood is strictly isolated from
TF to avoid unexpected clot formation [14]. In contrast, a
wide variety of blood cells, as well as endothelial cells, ex-
press TF under certain conditions [15,16]. The question
arises, however, as to what are the major cellular sourcesof TF in sepsis? Several cell types that are hemostatically
inactive under normal conditions can transform their
membrane into a powerful procoagulant surface when ex-
posed to agonists. In particular, endothelial cells and
mononuclear phagocytes have been intensively studied
and reported to induce synthesis of TF after exposure to
stimulating agents during sepsis [17]. Egorina and col-
leagues [18] reported that lipopolysaccharide induced TF
expression in human monocytes in vitro. TF expression
has also been observed in monocytes from patients with
bacteremia [19] or with viral infection [20]. As well as
hematopoietic cells, vascular endothelial cells also express
TF. One study reported co-localization of TF and von
Willebrand factor in the baboon model of sepsis [21].
In contrast, the ability of neutrophils to express TF has
been a matter of debate. Although Rapaport and Rao [22]
reported in 1995 that TF expressed in neutrophils plays an
important role in the activation of coagulation, the signifi-
cance of neutrophils in thrombus formation had been con-
sidered minor. Twenty years have passed since then, and
several studies have reported the in vivo and ex vivo
production of TF by neutrophils [23,24]. Maugeri and
colleagues [23] and Ritis and colleagues [24] reported that
neutrophils produce and express functional TF in response
to inflammatory agents, such as C5a, bacterial peptide
fMLP and P-selectin. Todoroki and colleagues [25] also
reported that TF-positive neutrophils were observed in the
circulation in a primate model of sepsis. We also recog-
nized TF expression on the cellular surface of the neutro-
phils stimulated by lipopolysaccharide (unpublished data;
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that neutrophils are the main source of blood-borne TF
using a thrombosis model. Moreover, neutrophils treated
with inflammatory mediators reportedly express TF at the
mRNA level. On the other hand, Osterud and colleagues
[27] reported that Escherichia coli phagocytosis in the ab-
sence of inflammatory mediators was not sufficient for TF
production, despite the observed upregulation of TF
mRNA, and this finding is in accordance with the previ-
ously reported inability of lipopolysaccharide-treated gran-
ulocytes to produce TF [28].
Other studies have also reported that neutrophils do not
synthesize TF, but can acquire TF by binding monocyte/
platelet-derived microparticles [29]. Regardless of whether
TF is produced de novo or is acquired from other sources,
we think neutrophil-derived TF plays some roles in coagu-
lopathy during sepsis since neutrophils are recognized as a
core part of thrombus formation. Indeed, it seems reason-
able to consider the activity of TF produced and/or ac-
quired by neutrophils as part of the pathogenesis of
thrombotic events during sepsis [30], since neutrophils
are the most abundant leukocyte population and enor-
mous numbers of neutrophils take part in the fight against
invading microorganisms at the front line of the infection
site. Further investigation is required to clarify the major
cellular source of septic coagulopathy.
Neutrophil extracellular trap formation
NETs, which are composed of nuclear and granule constit-
uents of neutrophils, were first described by Brinkmann
and colleagues [6]. They primarily entrap and dispose of
microbes, thereby contributing to host defense [31]. An al-
ternative effect of NETs is initiation of the coagulationneutrophbright field
Figure 2 Tissue factor expression by neutrophils. Representative micro
extracted from mouse were stimulated by lipopolysaccharide. Eight hours l
immunofluorescent antibodies to both neutrophil elastase (middle panel) a
agents, while lymphocytes (arrows) were negative for the staining.cascade [32,33]. The polyanionic NET surface readily acti-
vates contact phase proteins such as factor XII. The con-
tact system (intrinsic cascade) is initiated when blood
comes into contact with an anionic surface, and relies on
factors intrinsic to flowing blood. In contrast, the extrinsic
pathway has received its name because it is initiated by TF,
a protein that is not normally in contact with the blood-
stream. The participation of the contact pathway is dis-
pensable for physiological hemostasis, and its significance
with respect to its role in the activation of coagulation dur-
ing sepsis is still uncertain. Frick and colleagues [34] re-
ported that the contact system works as a branch of innate
immunity and is partly responsible for the activation of
sepsis-associated coagulopathy, although many others
think that its role is minor. Studies of experimental
bacteremia or endotoxemia have shown that activation of
coagulation under these circumstances is exclusively medi-
ated by the TF-VIIa route [35]. Blocking contact activation
by means of a monoclonal antibody to factor XIIa did not
affect E. coli-induced disseminated intravascular coagula-
tion in baboons [36]. Thus, further study is needed con-
cerning this issue.
NETs stimulate platelets via histones H3 and H4 to pro-
mote the thrombotic reaction [37]. Furthermore, a part of
the mechanism for activation of coagulation is explained
by the extracellular delivery of TF by NETs. Kambas and
colleagues [38] demonstrated the autophagy-mediated de-
livery of TF to NETs in sepsis patients. The role of NETs
was further examined using experimental models of deep
vein thrombosis [39]. These models have provided new in-
formation on the initiation and progression of clot forma-
tion and the specific impact of NETs; for example,
citrullinated histone H3 [40], which is a signature featureil elastase tissue factor
graphs of leukocytes (original magnification 100×). Leukocytes
ater, the neutrophils were fixed on the slide and stained with
nd tissue factor (right panel). The neutrophils were stained by both
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venous administration of histones accelerated clot forma-
tion [41]. In a mouse model of thrombosis induced by
lipopolysaccharide, the earliest event observed in the
vessel is the adhesion of leukocytes to endothelium, plate-
let aggregation and the subsequent endothelial damage
(Figure 3). These phenomena indicate the important role
of neutrophils in venous thrombus formation [42,43]. The
association of TF with NETs can also target thrombin gen-
eration and fibrin clot formation to the sites of infection
[4]. Kambas and colleagues [38,44] demonstrated that an
autophagy-based mechanism is implicated in the extracel-
lular localization of TF in NETs. The linkage between
NETs and thrombosis suggests a critical role for neutro-
phils in the interaction between inflammatory and throm-
botic pathways.
As well as TF expression on NETs, histones are also in-
volved in initiation of the coagulation cascade. According
to a report by Xu and colleagues [41], histones H3 and H4
have a highly damaging effect on endothelial cells; an in-
tense accumulation of neutrophils is seen in the lungs
when histones are injected intravenously into mice, and
peri-bronchoalveolar bleeding and thrombus formation is
observed, findings that were minimized when an antibody
against H4 was administered. We also confirmed the re-
markable lung edema, bleeding and thrombus formation
in a mouse model after the intravenous administration of
histone H3 [45] (Figure 4). Histones are DNA-binding
proteins with a positive charge and their toxicity can be
diminished by binding of heparins, which are highly sul-
fated and negatively charged. However, because high-dose
heparin increases the risk of bleeding, Wildhagen and col-
leagues [46] have developed nonanticoagulant heparin,
which was reported to improve survival in sepsis.Figure 3 Neutrophil adhesion to blood vessels. Left panel: intra-vital m
lipopolysaccharide infusion. The leukocyte (arrow) adheres to the endothelium
(objective lens × 20). Right panel: fluorescence live imaging of the mesenteric
microscopic examination was performed at 1 hour after infusion of lipop
damaged endothelial cells were also stained in blue (arrow head) (objectOther circulating NET components, such as nucleo-
somes and DNA, also activate the coagulation system,
and plasma samples obtained from severe sepsis patients
demonstrated the positive correlation between the nu-
cleosome and fibrin/fibrinogen degradation products
(FDPs), and histone H3 and FDPs (unpublished data;
Figure 5).
Histone/DNA complexes are potent activators of hu-
man platelets via Toll-like receptor-2 and −4. Histones
also interact with the A1 domain of von Willebrand factor,
leading to further acceleration of platelet activation [47].
Furthermore, histones induce endothelial cell cytotoxicity
and maximize the platelet-endothelial interaction [48].
Two serine protease components of NETs, neutrophil
elastase and cathepsin G, also contribute to coagulation
(discussed below).
As mentioned above, NET release is thought to play
important roles in the pathophysiology of sepsis and ac-
tivation of coagulation, although it remains controversial
whether NETs contribute significantly to sepsis-
associated coagulopathy and pathogen killing. To prove
the significance of NET release during sepsis, more so-
phisticated imaging techniques will be needed with ap-
propriate fluorescent dyes to delineate NETs.
As discussed, it is assumed that NETs play at least some
role in the development of sepsis-associated coagulopathy;
however, the contribution of neutrophils to the activation
of coagulation is not limited to infectious diseases. NETs
also contribute to coagulopathy in non-infectious diseases
such as autoimmune disease [49] and malignancies [50].
Kambas and colleagues [49] demonstrated that the expres-
sion of TF in NETs and neutrophil-derived microparticles
plays important roles in the induction of thrombosis in ac-
tive antibody-associated vasculitis.icroscopic view of the mouse mesenteric vein at 1 hour after
and the platelets aggregate in the surrounding area (arrow heads)
vein in mouse showing leukocytes in the thrombus (arrows). Fluorescent
olysaccharide and 4′,6-diamidino-2-phenylindole (DAPI). Nuclei of the
ive lens × 40).
50 mg/kgnormal
Figure 4 Histone H3-induced lung injury. Histological changes in mouse lung 3 hours after 50 mg/kg intravenous histone H3. Macroscopic
findings of the lung demonstrate massive bleeding and edema compared to the control (lower left corner). Remarkable bleeding was recognized
in the surrounding part of the trachea and the vessels microscopically. (Hematoxylin-eosin staining; ×20 objective lens).
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Microparticles are released from a variety of cells by bud-
ding of the plasma membrane, a process known as ‘ectocy-
tosis’ [51]. These microparticles express the specific antigens
of their parental cells [52], and their procoagulant activity
depends on negatively charged phospholipids, such as phos-
phatidylserine, TF, and inclusion proteins [44,53]. Circulating
levels of microparticles increase under critical conditions,
such as severe sepsis and disseminated intravascular coagu-
lation [54,55]. These reports indicate the substantial increase
in interest in the role of microparticles as effectors in the
tight tuning of adaptive responses such as inflammation, im-
munity, and hemostasis [56]. Among microparticles, TF-rich
microparticles have been investigated most thoroughly
[27,57]. Monocytes/macrophages have been suggested to be
the main source of TF-rich microparticles [58], although re-
cent studies have demonstrated that neutrophil-derived mi-
croparticles also express TF [44]. In addition, neutrophil-Figure 5 Relationship between fibrin/fibrinogen degradation product
nucleosome and histone H3 were measured in 10 patients (17 points) with
nucleosome and fibrin/fibrinogen degradation products (FDP; R2 = 0.258), a
neutrophil extracellular traps play some role in the activation of coagulatioderived microparticles expose phosphatidylserine on their
membrane [59] and contain bioactive enzymes such as neu-
trophil elastase and myeloperoxidase, which all contribute
to activation of coagulation [60]. The possibility of
neutrophil-derived microparticle-driven coagulation is fur-
ther supported by a report by Nieuwland and colleagues
[61]. They reported elevated levels of neutrophil-derived mi-
croparticles in septic patients with disseminated intravascu-
lar coagulation and suggested that the coagulation is
enhanced by phospholipid and surface TF on neutrophil-
derived microparticles. Although the results are not always
consistent [60,62], neutrophil-derived microparticles are, at
least to some degree, involved in the pathogenesis of coagu-
lation disorder during sepsis.
Serine proteases
In addition to the aforementioned mechanism of
neutrophil-transmitted activation of coagulation, protease-s and neutrophil extracellular traps. Circulating levels of
severe sepsis. Positive correlation was observed both between
nd between histone H3 and FDP (R2 = 0.459), suggesting that
n.
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elastase and cathepsin G are the two major proteases
related to coagulation, with neutrophil elastase considered
to be dominant. In mice lacking neutrophil elastase but
expressing cathepsin G, a significant reduction in fibrin
formation has been reported [63]. Neutrophil elastase asso-
ciated with NETs cleaves tissue factor pathway inhibitor
(TFPI) [63,64], a primary inhibitor of TF that is synthesized
mainly by endothelial cells and platelets and is presented in
the blood as well as on cell surfaces. The increased pro-
coagulant activity induced by the degradation of TFPI is
crucial for preventing the spread of invading microorgan-
isms. NET components cooperate efficiently to degrade
TFPI, and polyanionic nucleosomes, expelled along with
NET ejection, serve as the platform for the binding of neu-
trophil elastase [63]. In addition, neutrophil proteases have
been implicated in the control of platelet responses to vas-
cular injury by enhancing matrix thrombogenicity [65] and
also by the cleavage of von Willebrand factor [66]. It is an
intriguing scenario that two major bacteriocidal compo-
nents - the nucleosome and neutrophil elastase - cooperate
in clot formation to amplify the entrapment of microbes
and facilitate pathogen killing.
Another important function of neutrophil elastase is the
inactivation of anticoagulants. Plasma levels of physio-
logical anticoagulants such as antithrombin and activated
protein C are known to decrease markedly because of
their increased consumption, suppressed synthesis, and
degradation by neutrophil proteases [67]. Since the sup-
plementation of these anticoagulants is practically possible
and the development of other anticoagulants is currently
underway [68], determining the indication, timing and
dose for their use is quite important.
Conclusion
Immunothrombosis is a major element of the intravas-
cular innate immune system. Neutrophils expressing TF
are recruited into the circulatory system and the release
of TF-bearing neutrophil-derived microparticles, NETs
and their components intensifies activation of the coagu-
lation cascade, leading to thrombus formation and the
activation of other cell populations, such as platelets and
endothelial cells. These cellular and molecular responses
all participate in clot formation. In addition, neutrophil-
derived proteases, such as neutrophil elastase and ca-
thepsin G, further accelerate these sequential reactions.
However, the magnitude of the contribution of neutro-
phils to the activation of coagulation still remains to be
elucidated. The debate on the ability of neutrophils to
produce functional TF is ongoing, and the intracellular
localization of TF in neutrophils raises a concern regard-
ing its ability to activate the coagulation system. These is-
sues should be addressed in the future. Is the neutrophil a
‘prima donna’ or a ‘corps de ballet’ in the procoagulantprocess during sepsis? Further evidence is needed to an-
swer this question.
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